Introduction
Molecular farming is the production of recombinant pharmaceuticals, industrial proteins, and secondary metabolites, in plant systems. Since the biosynthesis of recombinant human growth hormone (hGH) by transgenic tobacco in 1986, a wide range of recombinant plant-made pharmaceuticals (PMPs) have been expressed in an increasingly diverse number of crops and vegetable systems [1] [2] [3] .
Transgenic plants are capable of folding and assembling complex structural glycoproteins -such as complete antibodies -and also of performing many of the post-translational modifications required for therapeutic function [2, 4] . Equally important is the fact that crops usually provide abundant biomass and have high biosynthetic capacity, requiring only simple elements such as light, minerals, and water to provide significant protein accumulation in their leaves, tubers, stems and seeds [1, 5] . In addition, advances in transient expression mediated by virus-infected plants can be exploited to obtain high yields of raw protein in only a few days, and this system may constitute the new frontier for the rapid, staggered production of therapeutic proteins, primarily vaccines, under competitive conditions [6] . Transient expres-
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sion allows the cultivation of transgenic plants under controlled conditions to be staggered, permitting the production of pharmaceutical-grade therapeutic proteins on a large scale and at competitive costs [6] [7] [8] .
Another important aspect of the production of therapeutic proteins in plants is the usually high safety standards of PMPs. In contrast to other available production platforms, notably the mammalian cell suspension, plants present a low risk of harboring mammalian pathogens, prions, human viruses, and oncogenes, providing a significant manufacturing advantage in terms of safety, quality, and product authenticity [9, 10] .
Interest in the potential of plants as biofactories for therapeutic proteins is growing rapidly, with the development of different expression strategies, improved production facilities, and an increase in capital expenditure by biotechnology companies around the world [2] . Recently, the recombinant enzyme glucocerebosidase (GCD), developed by the Israeli company Protalix Biotherapeutics under the registered name of ELELYSO TM , gained FDA approval for commercialization, becoming the first manufactured PMP to achieve marketable status [11] . ELELYSO TM is efficient in the treatment of type 1 Gaucher`s disease, a lysosomal storage disorder that affects macrophages, and was synthesized at an industrial scale using a carrot cell suspension system that uses the C-terminal vacuolar sorting signal from tobacco chitinase [12] . Another drug candidate developed by Protalix is the chimeric monoclonal antibody pr-antiTNF (tumor necrosis factor). The molecule is a biosimilar version of Pfizer Enbrel TM , a potent drug synthesized by Chinese hamster ovary (CHO) cells and utilized to treat chronic inflammatory disorders, such as rheumatoid arthritis [13] . Pr-anti -TNF was synthesized using the same technology as GCD, and presented the identical amino acid sequence and similar in vivo activity to Enbrel TM during preclinical trials (http://www.protalix.com/pipeline_products.html).
In 2010, after signing a Technology Investment Agreement grant of US$ 21 million with the Defense Advanced Research Projects Agency (DARPA), the Canadian company Medicago started the development of an H1N1 virus-like particle influenza vaccine using agroinfiltrated tobacco plants [11] . The main purpose of the agreement was the development of a quick manufacturing alternative in case of a pandemic, made possible by the rapid, agile, transient expression of the vaccine in the leaves within 24 h after infiltration [14] . The vaccine is now undergoing Phase I clinical trials and could be efficiently synthesized on an industrial scale (about 10 million doses in one month), representing, along with the company's previously H5N1 vaccine (currently in Phase II clinical trials), one of the most promising PMPs in the pipeline [14] . Other PMPs have reached advanced stages of development and are now undergoing approval for Phase III clinical trials prior to commercialization. These include vaccine antigens, antibodies, therapeutic enzymes, growth factors, hormones, cytokines and other proteins present in the human bloodstream [2, 3, 11, [15] [16] [17] .
Blood proteins are particularly interesting candidates for PMPs because they play key roles in metabolism and are associated with diseases that have significant social impact [18] . The different types of blood proteins can be divided into two major categories: (i) polypeptides associated with circulating cells; and (ii) plasma-derived proteins (PDs) that regulate important acellular processes, such as hormones, cytokines, enzymes, protease inhibitors, clotting factors, and bloodstream transporters of lipids, vitamins and ions [18] . Fractionated PDs are primarily utilized in the treatment of the different forms of acquired or congenital diseases, mainly the different forms of haemophilia and other bleeding and immunological disorders [18] . Also, this category of therapeutic proteins is invaluable for compensating for blood loss that results from trauma or surgery, in this way PDs contribute to saving and improving patients quality of life all over the globe [19] .
Despite the positive impact resulting from the routine utilization of PDs in human health care, the use of blood substitutes in the 1980s is linked to a considerable increase in the spread of viruses and other infectious diseases in America [20, 21] . In the two decades that followed, concerns about the safety of blood products resulted in the improvement of manipulating facilities and a strengthening of regulatory control over concentrate production [22] . Nowadays laboratories accredited to produce PDs must follow specific measures in compliance with good manufacturing practices (GMP), including the rigorous selection of blood donors, sample testing, and product treatment during manipulation [23] .
The adoption of GMP by manufacturers contributed to a consistent increase in the quality of products, but other issues still limit the large-scale production of PDs [20] . Despite the high demands of the market, manufactured PDs barely meet product demand and have high production costs, mostly due to the scarcity of well tested raw materials and the expensive multi-step fractioning/purification protocols required for drug manipulation [20] . Such limitations represent important challenges that have directed the scientific focus towards the development of alternative platforms for the recombinant production of PDs as virus-free products intended for replacement therapies [21, 24] .
Whereas bacterial and yeast cells are commonly utilized to produce many important recombinant therapeutic proteins, they are unable to provide the intricate folding and complex post-translational modifications required for most PDs [25, 26] . This gap was filled by cultured mammalian cells, which became the workhorse for recombinant plasma protein production. Mammalian cell suspensions are equipped with the specific enzymatic machinery capable of performing extensive post-translational modifications, mainly N-or O-glycosylation, similarly to those of human proteins [27, 28] . However, mam-malian cells present some drawbacks in terms of costeffectiveness, low cell density, and safety [25] .
Thus, transgenic plants may constitute promising alternative systems for the large-scale production of high quality recombinant PDs at accessible costs [26, [29] [30] [31] . In this review, we examine the technological approaches available for the production of cytokines using plant systems. We also evaluate some of the recent attempts to improve product quality in vegetable platforms, looking at the recent advances in the field that will potentially drive the development of the next generation of cytokines.
Cytokines produced by plant-based systems
Cytokines are soluble hormone-like proteins, which are frequently glycosylated, secreted primarily by white blood cells [32] . These molecules are synthesized and secreted at the femto to picomolar range in response to autocrine or paracrine inducible stimuli, and act as chemical signals between the cellular and external environments [33] . Human cytokines are components of the immune system and also regulate a broad range of processes as diverse as cell proliferation, differentiation, and mobility [34] [35] [36] . Abnormal fluctuations in cytokine production or signalling are related to various pathological immune and inflammatory disorders, such as major depression, cancer, and Alzheimer's disease [37] .
There are more than 100 well characterized cytokines, which can be conveniently grouped into eight distinct families distributed in two major functional classes [36] . Class I cytokines are the hematopoietins: (i) erythropoietin; (ii) cardiotrophin; (iii) macrophage colony-stimulating factor (M-CSF); (iv) granulocyte-macrophage colonystimulating factor (GM-CSF); and (v) interleukins (ILs) 2, 4, 12 and 13. The cytokines from Class II are: (i) the interferon (IFN) family (IFN-α, IFN-β, IFN-γ, IFN-κ and ILs 10, 20 and 22); (ii) the platelet-derived growth factors (PDGF); (iii) TNFs; (iv) IL-1; (v) IL-7; (vi) the tumor growth factor (TGF-beta) families; and (vii) the chemokines [36] .
The recombinant production of structurally simple cytokines traditionally relies on microbial systems [38] . For these simple cytokines the glycosylated products are active without the carbohydrate moiety or the hyperglycosylation provided by yeast does not interfere with the therapeutic function [25] . Cell suspensions of Escherichia coli and yeast are the most commonly utilized vehicles for the production of cytokines, and yields of more than 5 g of interferon per liter of cell culture are routinely obtained [39] . Although the expression levels associated with microbial systems are frequently high, the clinical usage of recombinant cytokines is still limited by high production costs [36] . Notwithstanding, different recombinant cytokines from microorganisms have been approved for clinical use in the treatment of neutropenia, leukemia, chronic hepatitis B and C [36] .
In contrast, while the first PMPs date from almost 25 years ago, the development of plant-derived cytokines is an emerging field in molecular farming, with a few examples of advanced drug candidates in the pipeline [36] . The drawbacks that limit the commercial success of cytokines produced in plant systems are similar to those encountered by any other class of PMPs. Commonly, the addition of undesirable plant glycosylation is a major concern related to the unsatisfactory therapeutic performance of many plant-derived cytokines [40, 41] . Although eukaryotes share many N-glycosylation steps along the secretory pathway, the final structures of N-complex glycans may differ considerably between plants and mammals [40] . In plants, the intermediate oligosaccharide GlcNAc 2 Man3GlcNAc 2 (GnGn) is usually decorated with β1,2-xylose and core α1,3-fucose residues [41] . Mammals also present core fucosylation, but only α1,6-fucose residues are processed in mammalian system. Further elongation can occur in plants, with the attachment of β1,3-galactose and α1,4-fucose residues to form Lewis-a epitopes (Le a ) [41] . The removal of terminal N acetylglucosamine (GlcNAc) from GnGn carbohydrates, resulting in the formation of paucimannosidic N-glycans, is another usual processing that may occur in plants [42] . Also, plants lack the machinery for mucin-type O-glycosylation [42] .
Major structural differences in glyco epitopes are frequently associated with protein instability, loss of biological function and immunogenicity. These represent important obstacles for manufacturing, and result in difficulties in standardization and validation of drug candidates [43] . However, several cytokines have already been synthesized in different plant systems, ranging from cell suspensions to transplastomic plants and virus-based production platforms for transient expression, as summarized in Table 1 .
Production of erythropoietin (EPO) in plants
EPO is an extensively glycosylated cytokine of 30 to 38 kDa that acts as a peptide hormone in the regulation of the differentiation of progenitor cells involved in the formation of mature erythrocytes [40] . The molecule is utilized in the treatment of anemia resulting from serious diseases, such as cancer, AIDS, and renal failure [44] .
Recombinant human EPO (rhEPO) from CHO cells has become an important therapeutic product on the market, with a business volume of about 8 billion US$ in 2003, and an estimated demand of 2 kg per year worldwide [45] . The rhEPOs display complex glycosylation with three N-linked (Asn-24, Asn-38 and Asn-83) and one O-linked (Ser-126) carbohydrate chains. The protein also requires sialylated N-glycans and processing of the carboxy-terminal arginine to be stable in the bloodstream and fully active [46, 47] .
The production of rhEPO in plants began in 1993, with the development of protoplasts derived from transgenic tobacco BY2 cell lines, which were capable of accumulating very low levels of rhEPO (approximately 1 × 10 -9 mg/g of wet cells) [48] . Similar levels (up to 1.2 × 10 -3 mg/L) were obtained from transgenic tobacco cell lines harboring the coding sequence of EPO and the endogenous N-terminal signal peptide for extracellular secretion under control of 35S promoter of cauliflower mosaic virus (CaMV). Secretion was observed in protoplasts derived from transgenic cells but the protein presented only showed activity in vitro [44] . The constitutive expression of rhEPO was also observed in whole plants of tobacco and Arabidopsis sp. Although high transcription levels were detected in all transgenic lines, tobacco plants presented abnormal morphology with retarded vegetative growth and male sterility [49] .
The initial setbacks in the development of functional rhEPO in plant systems corroborated the hypothesis that the differences in plant and mammalian glycosylation were crucial for the stability of the protein and for proper biological function [50] . To minimize such problems, different expression strategies have been developed in order to humanize plant glycosylation. One promising approach is to utilize the mutant moss Physcomitrella patens as a host for high quality production of rhEPO. An advantageous feature of P. patens is high frequency of homologous recombination for efficient gene targeting, enabling the specific knock out of the α1,3-fucosyltransferase and β1,2-xylosyltransferase genes [51] . For example, high levels of stable and transiently produced rhEPO (max. 0.250 mg/g dry weight) were achieved in protoplasts of wild-type and Δ-fuc-t Δ-xyl-t mutant lines of P. patens by Weise and collaborators [47] .
Another interesting strategy shown to be a promising tool for the generation of improved hEPO in plants is glycoengineering, the remodeling of complete mammalian biosynthetic pathways within host cells [45] . Transgenic tobacco lacking plant-specific glycosyltransferases and harboring mammalian β1,4-mannosyl-β,4-N-acetylglucosaminyltransferase (GnTIII), α1,3-mannosyl-β1,4-N-acetylglucosaminyltransferase (GnTIV) and α1,6-mannosyl-β1,6-N-acetylglucosaminyltransferase (GnTV) were utilized to modulate the plant glycosylation pathway toward the accumulation of rhEPO with complete human-type bisected and branched N-glycans [52] .
Along with N-glycosylation, terminal sialyation also seems to be crucial for the circulatory half-life and activity of rhEPO. Different glycoforms of biologically active biand multi-sialyated rhEPO were purified from mutant Δ-fuc-t Δ-xyl-t tobacco plants harboring the genes for branching, β1,4-galactosylation, synthesis, transport, and transfer of sialic acid [40, 45] . Examples of the improved recombinant production of EPO in glycoengineered plants are shown in Table 2 .
Production of human GM-CSF in plants
GM-CSFs are small proteins (22 kDa) secreted mainly by macrophages and T cells that act in the immune/inflammatory cascade [53] . GM-CSFs show little structural variation and are well tolerated by patients, thus constituting good candidates for PMPs [54] .
Tobacco and rice cell suspensions are the most commonly utilized systems for GM-CSF production, and different protocols for manipulation of the culture growth medium are available for improving expression levels [55, 56] . The rice amylase Ramy3D promoter is the most efficient genetic element used to increase the final GM-CSF expression in cell suspensions of rice, yielding up to 0.129 g/L of culture [57] . The silencing of rice α-amylase and cysteine proteinase combined with the co-expression of the cytokine and a protease inhibitor increases protein secretion and expression levels at least two-fold [58] .
Constitutive GM-CSF production in whole plants was also achieved, but at low levels. Transgenic sugarcane and tobacco plants were able to accumulate 0.02 and 0.22% TSP (total soluble protein) respectively in the leaves, whereas transgenic tobacco seeds produced up to 1.3% TSP [59, 60] . In fact, seed endosperm, rather than leaves, seems to be a more promising vehicle for the stable synthesis of GM-CSF. For instance, biologically active [36] . Max, maximum; IU, international unit. Note: All rhEPO information is in Table 2 Table 2 . fractions of this cytokine were obtained in rice seeds using the glutelin promoter Gt1 at 1.3% TSP [61] .
Production of ILs in plants
The normal function of the immune system depends largely on the synthesis of ILs, signaling proteins that are synthesized primarily by white blood cells [62] . Deficiency in IL production is associated with rare autoimmune diseases and immune failure. [63] . The first ILs expressed in plant systems were IL-2 and IL-4, which accumulated at low levels in tobacco cell suspensions [64] . In this example, most of the ILs were retained inside cells and only the secreted fractions presented biological function [64] . As alternatives to secretion, protein targeting and the synthesis of ILs as protein fusions seem to be promising strategies for improving recombinant IL production. The IL-2 targeted to the ER of potato tubers and the IL-4 fused to elastin in tobacco leaves presented high stability after translation, but were accumulated at low levels,115 U and 0.08% TSP, respectively [65, 66] .
Advances have also been made in the expression of plant-derived IL-10 and IL-12. Functional IL-10 has been produced in rice seeds (showing higher activity than the commercially available product from E. coli), and tobacco leaves (up to 0.037 mg/g of fresh weight) [67, 68] . Furthermore, high expression levels of fully active recombinant IL-12 were observed in tobacco leaves infiltrated with two Agrobacterium spp. strains (5% TSP) and in crude extracts of tomato (7.3 × 10 -3 mg/g) [69] [70] [71] . The tomato IL-12 also presented a biological function comparable with its commercial E. coli counterpart [71] . Other ILs such as IL-13 and IL-18, have also been stably produced in tobacco plants, but at low levels [72, 73] .
Boosting expression in chloroplasts of human interferons (IFNs) and insulin-like growth factor 1 (IGF-1)
Since the end of the 1990s, IFNs have been evaluated as potential candidates for molecular farming. IFNs present diverse molecular masses and are potent triggers of protective defenses of the immune system against pathogens and different types of tumors [74] . Recombinant IFNs from microbes are commonly used to treat Kaposi's sarcoma, myeloid leukaemia, and chronic hepatitis A and C, but microbial produced IFNs are expensive [75] .
Attempts to obtain a cost-effective IFN from plants have led to the development of Locteron ® , a recombinant IFN-α2b synthesized by the defunct company Biolex [11, 76] . The drug candidate is produced using the LEX system SM , a high-throughput platform that uses the aquatic plant Lemna minor, commonly known as duckweed, for the large-scale production of glycan engineered monoclonal antibodies and interferons [15] . Locteron ® has since Table 2 . Some of the glycoengineered plant systems developed for the humanized production of rhEPO and examples of fusion expression (continued). IGF-1 is a 7.6 kDa cytokine-like hormone structurally similar to insulin that mediates the anabolic action of the human growth hormone (hGH) and is utilized worldwide in the treatment of growth disorders during childhood [77] . Both, IFN-α2b and IGF-1, have been expressed in transgenic crops including: (i) potato tubers (560 IU of IFN-α2b/g); (ii) tomato and tobacco leaves (923 IU of IFN-α/g and 3 mg of IFN-α2b/g respectively); (iii) rice seeds (IGF-1, 6.8% TSP); and (iv) rice cell suspensions (up to 6.9 × 10 -4 ng of IFNγ/g) [78] [79] [80] [81] . Also, considerably high yields of functional IFN-α2b have been achieved by apoplast targeting in young carrot leaves (26.8 × 10 3 IU/g) and roots (8.56 x 10 3 IU/g) [82] .
Plant / Material
The stable transformation of the tobacco plastid genome has turned into a promising approach to increase the final yields of recombinant cytokines, especially IFNs and IGF-1 [83] . Homoplasmic transplastomic tobacco plants, developed by researchers at the University of Central Florida (US), could accumulate IFN-α2b at levels up to 20% TSP (3 mg/g of leaf FW) [84] . The molecules presented in vitro biological activity similar to the interferon marketed as PEG-Intron TM , a drug utilized to protect cells from cytopathic viral replication and inhibit early human immunodeficiency virus (HIV) infection [84] . Also, IFN-α2b presented in vivo antitumor protection. The transgenic plants expressing IFN-α2b received United States Department of Agriculture Animal and Plant Health Inspection Service (USDA-APHIS) approval for field growth, becoming the first example of field production of a plant-derived plasma protein, taking a crucial step towards clinical trials and commercialization [84] .
IGF-1 was also successfully accumulated in the chloroplasts of tobacco using the endogenous chloroplast psbA promoter. Final yields in routine cultivation were 11.3% TSP, but reached 32% TSP when plants were submitted to continuous photoperiod [85] .
Despite the myriad of reports of accumulation of PMPs in chloroplasts, there are no companies seeking to explore the chloroplast expression technology for cytokine production, as chloroplasts are unable to provide the complex post-translational modifications required for most cytokines to function properly in vivo [2, 86] .
Conclusions and perspectives
Among the novel classes of therapeutic molecules under development, recombinant proteins are the fastest growing candidates to fulfill customer demands [41] . The diversification of current plant-based expression systems and the improvement of existing technology platforms have allowed the development of new, efficient drug candidates. Some plant-produced drug candidates have reached advanced stages of preclinical trials and achieved basic commercial requirements such as high production speed, scalability, safety, high-quality manufacturing, and reduced costs [28] .
The introduction of the first PMP into the pharmaceutical market paves the way for the further development of recombinant cytokines. Recent progress in understanding the nature of many immune system disorders has contributed to a substantial increase in the demand for cytokines worldwide [11] . However, technical and regulatory challenges, mainly undesirable glycosylation, still limit the development of affordable products and make cytokine investment less attractive to investors, with some pioneering companies facing economic challenges or bankruptcy [2, 36] .
Protein targeting is an interesting strategy to avoid plant glycosylation but is insufficient when the cytokine of interest needs the correct galactosylation and sialylation for half-life and in vivo efficacy [43] . The utilization of Δ-fuc-t Δ-xyl-t mutant lines and those harboring GnTIII, GnTIV and GnTV has already proven to be suitable for the biosynthesis of functional cytokines, but such hosts strains are only available in a few plant systems, most notably tobacco and P. patens, therefore this technology is currently not applicable to other crops, such as cereals and legumes [41, 47, 51] .
In this context, zinc finger nucleases (ZFNs) and transcription activator-like effectors nucleases (TALENs) are promising molecular tools for the humanization of the N-glycosylation of cytokines in plants [87] . These DNAmodifying proteins enable the targeted alteration of genes in a wide range of cell types and organisms, with the potential to generate a substantial impact on the commercial production of PMPs [88] . Engineered ZFNs and TALENs can be designed to target any genomic location of interest, allowing genome editing with high accuracy and precision, even within complex genomes [89, 90] .
Genome editing promises to facilitate genetic manipulation of N-glycan associated genes to a much broader extent than the currently available molecular tools, potentially enhancing expression levels and permitting structural manipulation of complex cytokines without altering biological function.
Some plant systems still provide low yields of recombinant cytokines, limiting the commercial utilization of such systems due to production insufficient in speed and quantities to meet customer demands [36] . It is crucial to develop efficient strategies to boost recombinant expression of cytokines in order to achieve affordable manufacturing standards.
Recently, a new promising class of genetic tools related to the modulation of gene transcription was discovered in mammalian pluripotent cells: the super enhancers [91] .
These are unusual domains formed by clusters of enhancers up to 50 kb in size, which are densely occupied by master regulators involved in the activation of transcription in embryonic stem cells (ESCs) [92] . Super enhancers play key roles in gene expression and cell identity and can be explored, in the future, as a means to boost transcription of cytokine genes in different plant expression systems.
Genome-editing technology and strategies to boost recombinant expression in plants may constitute two powerful approaches for the large-scale production of recombinant cytokines with improved product quality and humanized post-translational modifications. We believe that both of these strategies represent the most exciting and promising subjects for future research in the field of molecular farming.
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